Patents by Inventor David H. Sherr
David H. Sherr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220323402Abstract: The invention is in the field of medical interventions, more in particular the treatment, amelioration or prevention of viral infections, such as Flavivirus infections, more in particular of infections with ZIKA virus. More in particular, the present description provides means and methods for the treatment, amelioration and prevention of congenital ZIKA virus syndrome. Even more in particular, the invention relates to an antagonist of the aryl hydrocarbon receptor (AHR) or a pharmaceutically acceptable salt thereof for use in the treatment, amelioration or prevention of viral infections such as Flavivirus infection, more in particular congenital ZIKA Virus (ZIKV) syndrome.Type: ApplicationFiled: April 26, 2022Publication date: October 13, 2022Inventors: Francisco Javier QUINTANA, David H. SHERR
-
Publication number: 20220177845Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.Type: ApplicationFiled: August 20, 2021Publication date: June 9, 2022Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 11124769Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.Type: GrantFiled: February 17, 2018Date of Patent: September 21, 2021Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITYInventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 10544393Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: GrantFiled: June 2, 2015Date of Patent: January 28, 2020Assignee: Boston Medical Center CorporationInventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 10314810Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.Type: GrantFiled: July 27, 2011Date of Patent: June 11, 2019Assignees: Trustees of Boston University, Northeastern University, Boston Medical Center CorporationInventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
-
Patent number: 10258600Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.Type: GrantFiled: March 3, 2016Date of Patent: April 16, 2019Assignees: Trustees of Boston University, Boston Medical Center, Northeastern UniversityInventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
-
Publication number: 20180291344Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.Type: ApplicationFiled: February 17, 2018Publication date: October 11, 2018Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 9919009Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: GrantFiled: June 2, 2015Date of Patent: March 20, 2018Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITYInventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 9896660Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.Type: GrantFiled: August 15, 2013Date of Patent: February 20, 2018Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITYInventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Publication number: 20160175278Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.Type: ApplicationFiled: March 3, 2016Publication date: June 23, 2016Applicants: Trustees of Boston University, Northeastern University, Boston Medical Center CorporationInventors: David H. SHERR, Michael POLLASTRI, Jennifer SCHLEZINGER, Sarah HAIGH MOLINA, Scott SCHAUS, Joshua Robert GIGUERE
-
Publication number: 20150335680Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: ApplicationFiled: June 2, 2015Publication date: November 26, 2015Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Publication number: 20150335682Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: ApplicationFiled: June 2, 2015Publication date: November 26, 2015Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Publication number: 20150203819Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.Type: ApplicationFiled: August 15, 2013Publication date: July 23, 2015Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 9074186Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: GrantFiled: March 14, 2013Date of Patent: July 7, 2015Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITYInventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Publication number: 20140050711Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: ApplicationFiled: March 14, 2013Publication date: February 20, 2014Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Publication number: 20130281525Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.Type: ApplicationFiled: July 27, 2011Publication date: October 24, 2013Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION, NORTHEASTERN UNIVERSITYInventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
-
MULTIPLE MYELOMA AND AL AMYLOID IMMUNOTHERAPY TARGETING IMMUNOGLOBULIN LIGHT CHAINS AND USES THEREOF
Publication number: 20090028847Abstract: The present invention relates generally to the prevention and treatment of disease states, and more particularly to the treatment and prevention of plasma cell disorders and plasma cell dyscrasias and other malignancies, amyloidosis and amyloid-associated diseases. In particular, the present invention relates to methods and compositions comprising immunogenic peptides for the treatment and prevention of diseases and malignancies, for example plasma cell disorders, plasma cell dyscrasias and amyloidosis or amyloid-associated diseases. The present invention also provides methods for an assay to screen for therapeutic vaccines for plasma cell disorders, plasma cell dyscrasias and amyloidosis or amyloid-associated diseases.Type: ApplicationFiled: April 14, 2008Publication date: January 29, 2009Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David H. Sherr, Amanda Flies